ArticleBone marrow transplantation2025
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.
Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.Bone marrow transplantation · 2025Pooled it
- Febrile neutropenia adversely affects chemomobilization outcomes in patients with multiple myeloma and increases risk for post-transplant infection in those with lymphoma: real-world multicenter data.Blood science (Baltimore, Md.) · 2026Article
- Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.Blood advances · 2026Article
- Classical Hodgkin Lymphoma Today.Mediterranean journal of hematology and infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated brentuximab vedotin (BV) as maintenance therapy after autologous stem cell transplantation (ASCT) in 353 patients with relapsed/refractory Hodgkin lymphoma (HL). Of these, 52.6% received BV prior to ASCT. The five-year overall survival (OS) and progression-free survival (PFS) from the start of BV maintenance were 85.1% and 69.9%, respectively. Multivariable analysis revealed that age at ASCT (HR 1.17, P = 0.037), disease status (HR 3.61, P = 0.002), and BV treatment before ASCT (HR 0.40, P = 0.033) significantly impacted OS. Disease status at ASCT was the only factor significantly associated with PFS (HR 3.09, p < 0.001) and relapse risk (HR 3.33, p < 0.001). Although a trend toward improved PFS (HR 0.59, p = 0.053) and lower relapse risk (HR 0.57, p = 0.051) was observed in patients treated with BV before ASCT, the data were not statistically significant. Patients in complete remission (CR) at ASCT showed similar 2-year OS (94.6% vs. 99.2%, P = 0.3) and PFS (84.6% vs. 89%, P = 0.3) regardless of BV pre-transplant. In those not in CR, OS (83.1% vs. 93.6%, P = 0.076) and PFS (51.5% vs. 75.3%, P = 0.039) were higher in those previously treated with BV. This large study emphasizes BV maintenance post-ASCT, even in patients pre-treated with BV, ang highlights disease status as a key prognostic factor.
Indexed as
Identifiers
40234724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.